Condition
Aicardi-Goutières Syndrome (AGS)
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05613868Phase 2TerminatedPrimary
TPN-101 in Aicardi-Goutières Syndrome (AGS)
NCT02363452Phase 2CompletedPrimary
Reverse Transcriptase Inhibitors in AGS
NCT06898372CompletedPrimary
Evaluate the Efficacy of Anti-Jak1 Inhibitors as Treatment for Patients With Aicardi-Goutières Syndrome
NCT01724580Unknown
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Showing all 4 trials